Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy --
-- Higher dose povetacicept (240 mg) administered once every four weeks currently being explored --
-- Based on this data Alpine will now seek to begin a pivotal phase 3 IgAN study in the second half of 2024 --
-- Company to host virtual investor call and webcast today at 4:30 pm ET with James Tumlin, M.D. and Jonathan Barratt, Ph.D., FRCP --
Investor Conference Call and Webcast Information
Date/Time: Thursday, November 2, 2023, at 4:30 pm – 5:30 pm ET
Alpine will host a conference call and webcast to discuss the data update from ASN as well as provide a corporate update. Members of the Alpine executive team will be joined by James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and Chief Executive Officer of NephroNet Clinical Trials Consortium, and Jonathan Barratt, Ph.D., FRCP, the Mayer Professor of Renal Medicine at the University of Leicester.
The link to the webcast is available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the live event.
https://www.businesswire.com/news/home/20231102047423/en/Figure
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.